ARENA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ARNA and Encourages Investors to Contact the Firm
Mightier Raises $17 Million to Support Growing Number of Kids Struggling with Emotional Health due to Pandemic
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Meta Platforms, Inc. f/k/a Facebook, Inc. with Losses of $500,000 to Contact the Firm
SoLVBL Solutions Launches AGORACOM Platform for Online Marketing and Verified Discussion Forum for Clean Social Media Engagement
Intuit QuickBooks Projects 17 Million New Entrepreneurs To Join Rapidly Growing Small Business Economy in 2022
New study finds procedures treating spinal fractures associated with reduction in opioid use and decreased payer costs
Jack Is Back! The Sans 2021 Holiday Hack Challenge, The Year's Most Fun & Festive Cybersecurity Challenge, Opens To Players Of All Skill Levels
Phase 2 Drilling to Start in January with Missinaibi Drilling Services, an Aboriginal-Owned Contractor
Aurora Cannabis Again Scores Highest Among Cannabis Corporate Boards in The Globe and Mail's Board Games Report
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
Nano One Announces Former U.S. Assistant Secretary of State for Energy Resources Frank Fannon as Strategic Advisor
Pilot Plant Ponds Under Construction, Drilling Campaign Accelerated & New Geophysics Commences - HMW Project Update
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
Bristol Myers Squibb's Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Meta Platforms, Inc. f.k.a. Facebook, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 27, 2021?- FB
Bronstein, Gewirtz & Grossman, LLC Reminds Meta Platforms, Inc. f/k/a Facebook, Inc. Shareholders With Losses Exceeding $1M of Class Action and Deadline: December 27, 2021
European Commission Approves Pfizer's Cibinqo® for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
Esports Entertainment Group Partnering with Hard Rock Hotel & Casino Atlantic City for First Sanctioned Esports Skill-Based Wagering Event in New Jersey
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
Cresco Labs Closes Acquisition of Pennsylvania Vertically Integrated Clinical Registrant, Laurel Harvest
Fission 3.0 Corp. and Traction Uranium Announce Option Agreements for Lazy Edward and Hearty Bay Projects
Star Diamond Corporation And Rio Tinto Announce Comprehensive Resolution Of All Disputes And Revised Joint Venture Arrangements
World Health Organization Strategic Advisory Group of Experts Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster